| Ytd | -67.75% | |
| 1y | -84.35% |
| Open | Prev Close | 5.16 | Low | High | Mkt Cap | 161.79M | |||
| Vol | 0.00 | Avg Vol | 905.22K | EPS | -3.60 | P/E | -1.43 | Forward P/E | -13.35 |
| Beta | 0.62 | Short Ratio | 13.18 | Inst. Own | 99.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-29 | 50-d Avg | 6.57 | 200-d Avg | 16.25 | 1yr Est | 54.25 |
LENZ News
HC Wainwright & Co. analyst Matthew Caufield reiterates LENZ Therapeutics (NASDAQ:LENZ) with
LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of
LENZ Therapeutics partners with Arrotex to commercialize VIZZ in Australia and New Zealand as analys
LENZ Therapeutics, Inc. (NASDAQ:LENZ) and Arrotex Pharmaceuticals Pty Ltd. ("Arrotex") today
Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowe
HC Wainwright & Co. analyst Matthew Caufield maintains LENZ Therapeutics (NASDAQ:LENZ) with a
Piper Sandler analyst Biren Amin downgrades LENZ Therapeutics (NASDAQ:LENZ) from Overweight to Ne
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.32) per share which missed the anal
